Johnson & Johnson SEC Filings

Johnson Paula A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Paula A. Johnson received a grant of 975 Deferred Share Units (DSUs) tied to the company’s common stock. These DSUs were awarded at no cash cost and will be settled in cash when her board service ends, based on the then-current share value.

After this grant and related dividend-equivalent accruals, she holds a total of 5,359.3973 DSUs, which track the value of Johnson & Johnson common stock but do not involve immediate share purchases or sales.

HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Marillyn A. Hewson received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. The DSUs were awarded at $0.00 per unit and are classified as derivative securities.

After this grant, Hewson holds a total of 15,487.939 DSUs. According to the plan terms, these DSUs will be settled in cash when her service as a director ends, with each DSU representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.

HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Marillyn A. Hewson received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. The DSUs were awarded at $0.00 per unit and are classified as derivative securities.

After this grant, Hewson holds a total of 15,487.939 DSUs. According to the plan terms, these DSUs will be settled in cash when her service as a director ends, with each DSU representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.

Doudna Jennifer A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Jennifer A. Doudna received a grant of 975 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors.

The DSUs are to be settled in cash when her board service ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date. Following this grant, she holds a total of 10,899.1714 DSUs, including units attributable to dividend equivalent rights that accrue in connection with the company’s quarterly dividend.

Doudna Jennifer A reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Jennifer A. Doudna received a grant of 975 Deferred Share Units (DSUs). These DSUs were awarded under the company’s Amended and Restated Deferred Fee Plan for Directors.

The DSUs are to be settled in cash when her board service ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date. Following this grant, she holds a total of 10,899.1714 DSUs, including units attributable to dividend equivalent rights that accrue in connection with the company’s quarterly dividend.

Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Mary C. Beckerle received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. After this award, she holds a total of 16,797.7393 DSUs. These DSUs will be settled in cash upon the end of her board service, with each DSU reflecting the fair market value of one J&J common share on the settlement date. The position also includes dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividends.

Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.

Johnson & Johnson director Mary C. Beckerle received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. After this award, she holds a total of 16,797.7393 DSUs. These DSUs will be settled in cash upon the end of her board service, with each DSU reflecting the fair market value of one J&J common share on the settlement date. The position also includes dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividends.

Johnson & Johnson reported the results of its 2026 Annual Meeting of Shareholders held on April 23, 2026. Shareholders elected all 12 director nominees to the Board of Directors, with each nominee receiving significantly more votes "For" than "Against."

Investors also approved, on an advisory basis, the company’s executive compensation program described in the 2026 Proxy Statement, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026. A shareholder proposal to adopt a policy requiring an independent board chair did not pass, receiving substantially more votes "Against" than "For."

Johnson & Johnson reported the results of its 2026 Annual Meeting of Shareholders held on April 23, 2026. Shareholders elected all 12 director nominees to the Board of Directors, with each nominee receiving significantly more votes "For" than "Against."

Investors also approved, on an advisory basis, the company’s executive compensation program described in the 2026 Proxy Statement, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026. A shareholder proposal to adopt a policy requiring an independent board chair did not pass, receiving substantially more votes "Against" than "For."

Johnson & Johnson reported mixed results for the fiscal first quarter ended March 29, 2026. Sales to customers reached $24,062 million, up from $21,893 million, driven by 11.2% growth in Innovative Medicine and 7.7% in MedTech. Oncology, neuroscience and pulmonary hypertension therapies showed strong increases, while some immunology products such as STELARA and XARELTO in cardiovascular declined.

Profitability was much lower than a year ago. Net earnings were $5,235 million versus $10,999 million, and diluted EPS was $2.14 compared with $4.54. The prior year included a large benefit from reversing approximately $7.0 billion of talc reserve and significant other income; the current quarter includes about $0.3 billion of talc-related charges.

Operating cash flow was $2,514 million, down from $4,174 million, as payables and accrued liabilities decreased. The company returned cash through $3,131 million in dividends and $4,028 million of share repurchases, while cash and cash equivalents rose to $21,688 million. Total assets were $200,894 million and total liabilities $119,708 million, leaving shareholders’ equity at $81,186 million.

Johnson & Johnson reported strong first-quarter 2026 growth, with reported sales rising 9.9% to $24.1 billion, driven by Innovative Medicine and MedTech. Diluted EPS under GAAP was $2.14, down from $4.54, while adjusted diluted EPS was $2.70, slightly below $2.77 a year earlier.

The company raised its 2026 outlook to estimated reported sales of $100.8 billion and adjusted EPS of $11.55, both implying around 7% growth at the midpoints. The Board also increased the quarterly dividend by 3.1%, from $1.30 to $1.34 per share, for an annual rate of $5.36 and a 64-year streak of consecutive dividend increases.

Johnson & Johnson reported strong first-quarter 2026 growth, with reported sales rising 9.9% to $24.1 billion, driven by Innovative Medicine and MedTech. Diluted EPS under GAAP was $2.14, down from $4.54, while adjusted diluted EPS was $2.70, slightly below $2.77 a year earlier.

The company raised its 2026 outlook to estimated reported sales of $100.8 billion and adjusted EPS of $11.55, both implying around 7% growth at the midpoints. The Board also increased the quarterly dividend by 3.1%, from $1.30 to $1.34 per share, for an annual rate of $5.36 and a 64-year streak of consecutive dividend increases.

Johnson & Johnson: Schedule 13G/A Amendment No. 10 — The Vanguard Group reports 0 shares (0%) beneficially owned.

The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The Vanguard Group certifies it no longer has beneficial ownership of the securities held by those subsidiaries and reports 0 shares beneficially owned as of the amendment signature date 03/26/2026.

Johnson & Johnson filed an amended Form 13F-HR restating and adding holdings information for its institutional investment manager report.

The amendment is Amendment No. 1, signed by Marc Larkins, Secretary on 03-18-2026. The Form 13F Information Table shows 17 entries with a total reported market value of $555,047,952. One other included manager is listed: Johnson & Johnson Innovation - JJDC, Inc.

Johnson & Johnson submitted an amended Form 13F-HR restating and updating its institutional holdings report. The amendment lists 20 holdings entries with a total reported value of $503,922,707 and identifies 1 other included manager, Johnson & Johnson Innovation - JJDC, Inc.

The report is signed by Marc Larkins, Secretary, and the filing indicates it adds new holdings entries as part of the amendment.